Reliance on endogenous insulin remains a significant challenge for individuals with type 1 diabetes (T1D). Although current rapid-acting insulin analogs (RAA) and ultra-rapid-acting insulin analogs (URAA) can provide effective postprandial glycemic control, inaccurate calculation of carbohydrates and mistiming of insulin injections can result in postprandial glucose spikes or early hypoglycemia. Their long duration of action also raises concerns about insulin stacking, which may result in late postprandial hypoglycemia. Unlike injected or infused rapid-acting insulins, Technosphere® insulin (TI) may bypass the slower absorption and hepatic degradation associated with subcutaneous delivery, ensuring faster systemic availability, however definitive studies have not been conducted. This characteristic of TI aligns closely with the timing of ketone body production, enabling timely intervention to prevent progression to full-blown ketoacidosis. The RAA and URAA profile characteristics are also problematic for individuals who engage in regular physical activity, often resulting in hypoglycemia, hyperglycemia, or both. This article reviews the challenges and potential dangers associated with managing T1D and discusses how TI, the only commercially available inhaled insulin, may overcome the inherent limitations of current RAA and URAA therapies.
HeinemannL, BaughmanR, BossA, HompeschM. Pharmacokinetic and pharmacodynamic properties of a novel inhaled insulin. J Diabetes Sci Technol, 2017; 11(1):148–156; doi: 10.1177/1932296816658055
2.
RaskinP, HellerS, HonkaM, et al.Pulmonary function over 2 years in diabetic patients treated with prandial inhaled Technosphere Insulin or usual antidiabetes treatment: A randomized trial. Diabetes Obes Metab, 2012; 14(2):163–173; doi: 10.1111/j.1463-1326.2011.01500.x
Potocka E, Hovorka R, Baughman RA, et al. Characterization of Metabolism Parameters Following Technosphere (R) Insulin and Insulin Lispro. Diabetes 2010;59:A413.
10.
GrantM, HeiseT, BaughmanR. Comparison of Pharmacokinetics and Pharmacodynamics of Inhaled Technosphere Insulin and Subcutaneous Insulin Lispro in the Treatment of Type 1 Diabetes Mellitus. Clin Pharmacokinet, 2022; 61(3):413–422; doi: 10.1007/s40262-021-01084-0
11.
PuchalskaP, CrawfordPA. Multi-dimensional roles of ketone bodies in fuel metabolism, signaling, and therapeutics. Cell Metab, 2017; 25(2):262–284; doi: 10.1016/j.cmet.2016.12.022
12.
CahillGF.Jr., Fuel metabolism in starvation. Annu Rev Nutr, 2006; 26:1–22; doi: 10.1146/annurev.nutr.26.061505.111258
GosmanovAR, GosmanovaEO, KitabchiAE. Hyperglycemic crises: diabetic ketoacidosis and hyperglycemic hyperosmolar state. In: Endotext. (FeingoldKR, AhmedSF, AnawaltB, et al. eds.) MDText.com, Inc.: South Dartmouth, MA; 2000. Available from: https://endotext.org/wp-content/uploads/pdfs/hyperglycemic-crises-diabetic-ketoacidosis-dka-and-hyperglycemic.pdf
15.
American Diabetes Association. Glycemic goals and hypoglycemia: Standards of care in diabetes—2025. Diabetes Care, 2025; 48(Supplement_1):S128–S145; doi: 10.2337/dc25-S006
FayfmanM, PasquelFJ, UmpierrezGE. Management of hyperglycemic crises: Diabetic ketoacidosis and hyperglycemic hyperosmolar state. Med Clin North Am, 2017; 101(3):587–606; doi: 10.1016/j.mcna.2016.12.011
18.
KitabchiAE, UmpierrezGE, MilesJM, FisherJN. Hyperglycemic crises in adult patients with diabetes. Diabetes Care, 2009; 32(7):1335–1343; doi: 10.2337/dc09-9032
19.
KitabchiAE, UmpierrezGE, FisherJN, et al.Thirty years of personal experience in hyperglycemic crises: Diabetic ketoacidosis and hyperglycemic hyperosmolar state. J Clin Endocrinol Metab, 2008; 93(5):1541–1552; doi: 10.1210/jc.2007-2577
20.
GoguenJ, GilbertJ, Diabetes Canada Clinical Practice Guidelines Expert Committee. Hyperglycemic emergencies in adults. Can J Diabetes, 2018; 42(Suppl 1):S109–S114; doi: 10.1016/j.jcjd.2017.10.013
21.
ShandJAD, MorrowP, BraatvedtG. Mortality after discharge from hospital following an episode of diabetic ketoacidosis. Acta Diabetol, 2022; 59(11):1485–1492; doi: 10.1007/s00592-022-01953-5
22.
McCoyRG, HerrinJ, GalindoRJ, et al.All-cause mortality after hypoglycemic and hyperglycemic emergencies among U.S. adults with diabetes, 2011–2020. Diabetes Res Clin Pract, 2023; 197:110263; doi: 10.1016/j.diabres.2023.110263
23.
GibbFW, TeohWL, GrahamJ, LockmanKA. Risk of death following admission to a UK hospital with diabetic ketoacidosis. Diabetologia, 2016; 59(10):2082–2087; doi: 10.1007/s00125-016-4034-0
24.
HammersenJ, TittelSR, WarnckeK, et al.; DPV Initiative. Previous diabetic ketoacidosis as a risk factor for recurrence in a large prospective contemporary pediatric cohort: Results from the DPV initiative. Pediatr Diabetes, 2021; 22(3):455–462; doi: 10.1111/pedi.13185
25.
PlewaMC, BryantM, King-ThieleR. Euglycemic diabetic ketoacidosis. In: StatPearls. StatPearls Publishing: Treasure Island, FL; 2022. Available from: https://www.ncbi.nlm.nih.gov/books/NBK554570/
26.
RamaeshA. Incidence and long-term outcomes of adult patients with diabetic ketoacidosis admitted to intensive care: A retrospective cohort study. J Intensive Care Soc, 2016; 17(3):222–233; doi: 10.1177/1751143716644458
27.
KostopoulouE, SinopidisX, FouzasS, et al.Diabetic ketoacidosis in children and adolescents; diagnostic and therapeutic pitfalls. Diagnostics (Basel), 2023; 13(15):2602; doi: 10.3390/diagnostics13152602
28.
VirdiN, PoonY, AbanielR, BergenstalRM. Prevalence, cost, and burden of diabetic ketoacidosis. Diabetes Technol Ther, 2023; 25(S3):S75–S84; doi: 10.1089/dia.2023.0149
29.
EdgeJA, HawkinsMM, WinterDL, DungerDB. The risk and outcome of cerebral oedema developing during diabetic ketoacidosis. Arch Dis Child, 2001; 85(1):16–22. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11420189
30.
GlaserN, BarnettP, McCaslinI, et al.; Pediatric Emergency Medicine Collaborative Research Committee of the American Academy of Pediatrics. Risk factors for cerebral edema in children with diabetic ketoacidosis. The pediatric emergency medicine Collaborative Research Committee of the American Academy of Pediatrics. N Engl J Med, 2001; 344(4):264–269; doi: 10.1056/NEJM200101253440404
31.
DucaLM, WangB, RewersM, RewersA. Diabetic ketoacidosis at diagnosis of type 1 diabetes predicts poor long-term glycemic control. Diabetes Care, 2017; 40(9):1249–1255; doi: 10.2337/dc17-0558
32.
ShalitinS, FisherS, Yackbovitch-GavanM, et al.Ketoacidosis at onset of type 1 diabetes is a predictor of long-term glycemic control. Pediatr Diabetes, 2018; 19(2):320–328; doi: 10.1111/pedi.12546
33.
AyeT, MazaikaPK, MaurasN, et al.; Diabetes Research in Children Network (DirecNet) Study Group. Impact of early diabetic ketoacidosis on the developing brain. Diabetes Care, 2019; 42(3):443–449; doi: 10.2337/dc18-1405
34.
HeinemannL, ParkinCG. Rethinking the viability and utility of inhaled insulin in clinical practice. J Diabetes Res, 2018; 2018:4568903; doi: 10.1155/2018/4568903
35.
LeonardT. The physiology of ketosis and ketogenic diet. South Afr J Anaesth Analg, 2020; 26(6 Suppl 3):S94–S97; doi: 10.36303/SAJAA.2020.26.6.S3.2547
36.
BellDSH, GoncalvesE. Case report: Efficient avoidance of hospitalization for diabetic ketosis utilizing Technosphere inhaled insulin. Diabetes Ther, 2020; 11(5):1175–1177; doi: 10.1007/s13300-020-00809-x
37.
RiddellMC, GallenIW, SmartCE, et al.Exercise management in type 1 diabetes: A consensus statement. Lancet Diabetes Endocrinol, 2017; 5(5):377–390; doi: 10.1016/S2213-8587(17)30014-1
38.
RiddellMC, PetersAL. Exercise in adults with type 1 diabetes mellitus. Nat Rev Endocrinol, 2023; 19(2):98–111; doi: 10.1038/s41574-022-00756-6
39.
RothmanDL, MagnussonI, KatzLD, et al.Quantitation of hepatic glycogenolysis and gluconeogenesis in fasting humans with 13C NMR. Science, 1991; 254(5031):573–576; doi: 10.1126/science.1948033
40.
ChokkalingamK, TsintzasK, NortonL, et al.Exercise under hyperinsulinaemic conditions increases whole-body glucose disposal without affecting muscle glycogen utilisation in type 1 diabetes. Diabetologia, 2007; 50(2):414–421; doi: 10.1007/s00125-006-0520-0
41.
MalladA, HinshawL, SchiavonM, et al.Exercise effects on postprandial glucose metabolism in type 1 diabetes: A triple-tracer approach. Am J Physiol Endocrinol Metab, 2015; 308(12):E1106–E1115; doi: 10.1152/ajpendo.00014.2015
42.
RiddellMC, ScottSN, FournierPA, et al.The competitive athlete with type 1 diabetes. Diabetologia, 2020; 63(8):1475–1490.
43.
AronsonR, BrownRE, LiA, RiddellMC. Optimal insulin correction factor in post-high-intensity exercise hyperglycemia in adults with type 1 diabetes: The FIT Study. Diabetes Care, 2019; 42(1):10–16; doi: 10.2337/dc18-1475
44.
RiddellMC, PooniR, YavelbergL, et al.Reproducibility in the cardiometabolic responses to high-intensity interval exercise in adults with type 1 diabetes. Diabetes Res Clin Pract, 2019; 148:137–143; doi: 10.1016/j.diabres.2019.01.003
45.
FéryF, De MaertelaerV, BalasseEO. Mechanism of the hyperketonaemic effect of prolonged exercise in insulin-deprived type 1 diabetic patients. Diabetologia, 1987; 30(5):298–304; doi: 10.1007/BF00299021
46.
WahrenJ, SatoY, ÖstmanJ, et al.Turnover and splanchnic metabolism of free fatty acids and ketones in insulin-dependent diabetics at rest and in response to exercise. J Clin Invest, 1984; 73(5):1367–1376; doi: 10.1172/JCI111340
47.
van AlbadaME, Bakker-van WaardeWM. Recurrent nightly ketosis after prolonged exercise in type 1 diabetes—the need for glycogen replacement strategies: Case report and review of the literature. Pediatr Diabetes, 2016; 17(7):531–534; doi: 10.1111/pedi.12328
48.
MoserO, ZaharievaDP, AdolfssonP, BattelinoT, et al.The use of automated insulin delivery around physical activity and exercise in type 1 diabetes: a position statement of the European Association for the Study of Diabetes (EASD) and the International Society for Pediatric and Adolescent Diabetes (ISPAD). Diabetologia, 2025; 68(2):255–280; doi: 10.1007/s00125-024-06308-z
